{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:13:07Z","timestamp":1780751587762,"version":"3.54.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","award":["Gateway to Research Awards 2022 - 2023"],"award-info":[{"award-number":["Gateway to Research Awards 2022 - 2023"]}],"id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009508","name":"Skaggs School of Pharmacy and Pharmaceutical Sciences","doi-asserted-by":"publisher","award":["Summer Research Program 2022"],"award-info":[{"award-number":["Summer Research Program 2022"]}],"id":[{"id":"10.13039\/100009508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40258-025-00991-8","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T17:45:00Z","timestamp":1753033500000},"page":"1115-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing Naloxone Distribution for Opioid Users in the USA: A Cost-Utility Analysis of Academic Detailing to Clinicians"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0090-8530","authenticated-orcid":false,"given":"Olivia","family":"Yip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-9458","authenticated-orcid":false,"given":"Mark","family":"Bounthavong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"991_CR1","unstructured":"National Institute on Drug Abuse. Drug overdose death rates. 2024. Available from: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"991_CR2","unstructured":"Hargan ED. HHS acting secretary declares public health emergency to address national opioid crisis. 2017. Available from: https:\/\/public3.pagefreezer.com\/browse\/HHS.gov\/31-12-2020T08:51\/https:\/\/www.hhs.gov\/about\/news\/2017\/10\/26\/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html"},{"key":"991_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/1559827618803874","volume":"13","author":"ND White","year":"2018","unstructured":"White ND. Increasing naloxone access and use to prevent opioid overdose death and disability. Am J Lifestyle Med. 2018;13:33\u20135.","journal-title":"Am J Lifestyle Med"},{"key":"991_CR4","unstructured":"Expanding access to naloxone: a review of distribution strategies. Penn LDI. 2019. Available from: https:\/\/ldi.upenn.edu\/our-work\/research-updates\/expanding-access-to-naloxone-a-review-of-distribution-strategies\/"},{"key":"991_CR5","first-page":"101","volume":"61","author":"E Wheeler","year":"2012","unstructured":"Wheeler E, Davidson PJ, Jones TS, Irwin KS. Community-based opioid overdose prevention programs providing Naloxone \u2014 United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:101\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"991_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2146\/ajhp130798","volume":"71","author":"A Robinson","year":"2014","unstructured":"Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm. 2014;71:2129\u201335.","journal-title":"Am J Health Syst Pharm"},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3109\/10903127.2015.1076096","volume":"20","author":"SA Sumner","year":"2016","unstructured":"Sumner SA, Mercado-Crespo MC, Spelke MB, Paulozzi L, Sugerman DE, Hillis SD, et al. Use of naloxone by emergency medical services during opioid drug overdose resuscitation efforts. Prehosp Emerg Care. 2016;20:220\u20135.","journal-title":"Prehosp Emerg Care"},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, et al. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111:e1-12.","journal-title":"Am J Public Health"},{"key":"991_CR9","doi-asserted-by":"crossref","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4688551\/","DOI":"10.1136\/bmj.f174"},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.annemergmed.2006.05.025","volume":"49","author":"KA Sporer","year":"2007","unstructured":"Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med. 2007;49:172\u20137.","journal-title":"Ann Emerg Med"},{"key":"991_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.39427","volume":"7","author":"CB Gage","year":"2024","unstructured":"Gage CB, Powell JR, Ulintz A, Cash RE, Lyons MS, Wang H, et al. Layperson-administered naloxone trends reported in emergency medical service activations, 2020\u20132022. JAMA Netw Open. 2024;7: e2439427.","journal-title":"JAMA Netw Open"},{"key":"991_CR12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.15585\/mmwr.mm6731a2","volume":"67","author":"RE Cash","year":"2018","unstructured":"Cash RE, Kinsman J, Crowe RP, Rivard MK, Faul M, Panchal AR. Naloxone administration frequency during emergency medical service events\u2014United States, 2012\u20132016. MMWR Morb Mortal Wkly Rep. 2018;67:850\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"991_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0117","volume":"3","author":"JG Katzman","year":"2020","unstructured":"Katzman JG, Takeda MY, Greenberg N, Moya Balasch M, Alchbli A, Katzman WG, et al. Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program. JAMA Netw Open. 2020;3: e200117.","journal-title":"JAMA Netw Open"},{"key":"991_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","volume":"158","author":"PO Coffin","year":"2013","unstructured":"Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1\u20139.","journal-title":"Ann Intern Med"},{"key":"991_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3111\/13696998.2013.811080","volume":"16","author":"PO Coffin","year":"2013","unstructured":"Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J Med Econ. 2013;16:1051\u201360.","journal-title":"J Med Econ"},{"key":"991_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jval.2019.12.002","volume":"23","author":"M Acharya","year":"2020","unstructured":"Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-effectiveness of intranasal naloxone distribution to high-risk prescription opioid users. Value Health. 2020;23:451\u201360.","journal-title":"Value Health."},{"key":"991_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.105932","volume":"130","author":"CS Davis","year":"2020","unstructured":"Davis CS, Carr D. Over the counter naloxone needed to save lives in the United States. Prev Med. 2020;130: 105932.","journal-title":"Prev Med"},{"key":"991_CR18","first-page":"13","volume":"10","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Hill LG, Davis CS. Considering the potential benefits of over-the-counter naloxone. Integr Pharm Res Pract. 2021;10:13\u201321.","journal-title":"Integr Pharm Res Pract."},{"key":"991_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2024.8323","volume":"332","author":"SM Rikard","year":"2024","unstructured":"Rikard SM, Strahan AE, Schieber LZ, Guy GP Jr. Trends in naloxone dispensing from retail pharmacies in the US. JAMA. 2024;332:165\u20137.","journal-title":"JAMA"},{"key":"991_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100126","volume":"6","author":"RM Bohler","year":"2022","unstructured":"Bohler RM, Freeman PR, Villani J, Hunt T, Linas BS, Walley AY, et al. The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses. Drug Alcohol Depend Reports. 2022;6: 100126.","journal-title":"Drug Alcohol Depend Reports."},{"key":"991_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.7326\/M23-0852","volume":"176","author":"JC Messinger","year":"2023","unstructured":"Messinger JC, Beletsky L, Kesselheim AS, Barenie RE. Moving naloxone over the counter is necessary but not sufficient. Ann Intern Med. 2023;176:1109\u201312.","journal-title":"Ann Intern Med"},{"key":"991_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13722-016-0068-3","volume":"12","author":"T Kerensky","year":"2017","unstructured":"Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don\u2019t know. Addict Sci Clin Pract. 2017;12:4.","journal-title":"Addict Sci Clin Pract"},{"key":"991_CR23","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00304-2","volume":"7","author":"MA Irvine","year":"2022","unstructured":"Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022;7:e210\u20138.","journal-title":"Lancet Public Health."},{"key":"991_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2105\/AJPH.2016.303062","volume":"106","author":"CM Jones","year":"2016","unstructured":"Jones CM, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health. 2016;106:689.","journal-title":"Am J Public Health"},{"issue":"60","key":"991_CR25","first-page":"1001","volume":"2020","author":"CD Saffore","year":"2003","unstructured":"Saffore CD, Pickard AS, Crawford SY, Fischer MA, Sharp LK, Lee TA. Practice change intentions after academic detailing align with subsequent opioid prescribing. J Am Pharm Assoc. 2003;2020(60):1001\u20138.","journal-title":"J Am Pharm Assoc"},{"issue":"Suppl 2","key":"991_CR26","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1111\/j.1526-4637.2011.01125.x","volume":"12","author":"S Cochella","year":"2011","unstructured":"Cochella S, Bateman K. Provider detailing: an intervention to decrease prescription opioid deaths in Utah. Pain Med. 2011;12(Suppl 2):S73-76.","journal-title":"Pain Med"},{"issue":"57","key":"991_CR27","first-page":"S68","volume":"2017","author":"M Bounthavong","year":"2003","unstructured":"Bounthavong M, Harvey MA, Wells DL, Popish SJ, Himstreet J, Oliva EM, et al. Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: a preliminary analysis. J Am Pharm Assoc. 2003;2017(57):S68-72.","journal-title":"J Am Pharm Assoc"},{"key":"991_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/1475-6773.13194","volume":"54","author":"M Bounthavong","year":"2019","unstructured":"Bounthavong M, Devine EB, Christopher MLD, Harvey MA, Veenstra DL, Basu A. Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Serv Res. 2019;54:1055\u201364.","journal-title":"Health Serv Res"},{"key":"991_CR29","first-page":"42","volume":"9","author":"JS Yeh","year":"2016","unstructured":"Yeh JS, Van Hoof TJ, Fischer MA. Key features of academic detailing: development of an expert consensus using the Delphi Method. Am Health Drug Benefits. 2016;9:42\u201350.","journal-title":"Am Health Drug Benefits."},{"key":"991_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jama.1990.03440040088034","volume":"263","author":"SB Soumerai","year":"1990","unstructured":"Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing\u2019) to improve clinical decision making. JAMA. 1990;263:549\u201356.","journal-title":"JAMA"},{"key":"991_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/jama.2016.16036","volume":"317","author":"J Avorn","year":"2017","unstructured":"Avorn J. Academic detailing: \u201cmarketing\u201d the best evidence to clinicians. JAMA. 2017;317:361\u20132.","journal-title":"JAMA"},{"key":"991_CR32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJM198306163082406","volume":"308","author":"J Avorn","year":"1983","unstructured":"Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based \u201cdetailing.\u201d N Engl J Med. 1983;308:1457\u201363.","journal-title":"N Engl J Med"},{"key":"991_CR33","first-page":"16","volume":"39","author":"MAE Zagaria","year":"2014","unstructured":"Zagaria MAE. Academic detailing: accurate, relevant, balanced, and engaging. US Pharmacist. 2014;39:16\u20139.","journal-title":"US Pharmacist."},{"key":"991_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta8060","volume":"8","author":"JM Grimshaw","year":"2004","unstructured":"Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8:1\u201372 (iii\u2013iv).","journal-title":"Health Technol Assess"},{"key":"991_CR35","doi-asserted-by":"publisher","first-page":"II55","DOI":"10.1097\/00005650-200108002-00004","volume":"39","author":"PA Gross","year":"2001","unstructured":"Gross PA, Pujat D. Implementing practice guidelines for appropriate antimicrobial usage: a systematic review. Med Care. 2001;39:II55\u201369.","journal-title":"Med Care"},{"key":"991_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/her\/cyn004","volume":"23","author":"RP Hawkins","year":"2008","unstructured":"Hawkins RP, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res. 2008;23:454\u201366.","journal-title":"Health Educ Res"},{"key":"991_CR37","first-page":"122","volume":"49","author":"E Behar","year":"2017","unstructured":"Behar E, Rowe C, Santos G-M, Santos N, Coffin PO. Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco. Fam Med. 2017;49:122\u20136.","journal-title":"Fam Med"},{"key":"991_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11916-018-0730-4","volume":"22","author":"A Abd-Elsayed","year":"2018","unstructured":"Abd-Elsayed A, Albert CA, Fischer M, Anderson B. Naloxone academic detailing: role of community outreach teaching. Curr Pain Headache Rep. 2018;22:72.","journal-title":"Curr Pain Headache Rep"},{"issue":"57","key":"991_CR39","first-page":"S168","volume":"2017","author":"EM Oliva","year":"2003","unstructured":"Oliva EM, Christopher MLD, Wells D, Bounthavong M, Harvey M, Himstreet J, et al. Opioid overdose education and naloxone distribution: development of the Veterans Health Administration\u2019s national program. J Am Pharm Assoc. 2003;2017(57):S168\u201379 (e4).","journal-title":"J Am Pharm Assoc"},{"key":"991_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/j.pain.0000000000000837","volume":"158","author":"LA Lin","year":"2017","unstructured":"Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the Opioid Safety Initiative on opioid-related prescribing in veterans. Pain. 2017;158:833\u20139.","journal-title":"Pain"},{"key":"991_CR41","doi-asserted-by":"publisher","unstructured":"Williams EC, Frost MC, Bounthavong M, Edmonds AT, Lau MK, Edelman EJ, Harvey MA, Christopher MLD. Implementation of Opioid Safety Efforts: Influence of Academic Detailing on Adverse Outcomes Among Patients in the Veterans Health Administration. Subst Use Addctn J. 2024 Oct;45(4):610\u201323. https:\/\/doi.org\/10.1177\/29767342241243309. Epub 2024 Apr 18. PMID: 38634339.","DOI":"10.1177\/29767342241243309"},{"key":"991_CR42","unstructured":"U.S. Food and Drug Administration. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. FDA. 2022; Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain"},{"key":"991_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10\u201331.","journal-title":"Value Health."},{"key":"991_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jval.2017.12.006","volume":"21","author":"LP Garrison","year":"2018","unstructured":"Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context\u2014a health economics approach: an ISPOR special task force report [2]. Value in Health. 2018;21:124\u201330.","journal-title":"Value in Health"},{"key":"991_CR45","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/QAD.0000000000002803","volume":"35","author":"SD Kimmel","year":"2021","unstructured":"Kimmel SD, Walley AY, Lodi S, Forman LS, Liebschutz JM, Lira MC, et al. Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. AIDS. 2021;35:697\u2013700.","journal-title":"AIDS"},{"key":"991_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11606-020-05872-5","volume":"36","author":"AW Roberts","year":"2021","unstructured":"Roberts AW. Naloxone prescribing among frequent opioid prescribers in medicare part D from 2013 to 2017: a retrospective study. J Gen Intern Med. 2021;36:543\u20135.","journal-title":"J Gen Intern Med"},{"key":"991_CR47","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1007\/s11606-020-06577-5","volume":"36","author":"BD Stein","year":"2021","unstructured":"Stein BD, Smart R, Jones CM, Sheng F, Powell D, Sorbero M. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. J Gen Intern Med. 2021;36:2952\u20137.","journal-title":"J Gen Intern Med"},{"key":"991_CR48","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/add.14964","volume":"115","author":"AY Walley","year":"2020","unstructured":"Walley AY, Lodi S, Li Y, Bernson D, Babakhanlou-Chase H, Land T, et al. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020;115:1496\u2013508.","journal-title":"Addiction"},{"key":"991_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"991_CR50","unstructured":"U.S. Department of Veterans Affairs. Office of Procurement, Acquisition and Logistics (OPAL) - Pharmaceutical Prices. Available from: https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp"},{"key":"991_CR51","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1093\/pm\/pny085","volume":"19","author":"AM Midboe","year":"2018","unstructured":"Midboe AM, Wu J, Erhardt T, Carmichael JM, Bounthavong M, Christopher MLD, et al. Academic detailing to improve opioid safety: implementation lessons from a qualitative evaluation. Pain Med. 2018;19:S46-53.","journal-title":"Pain Med"},{"key":"991_CR52","first-page":"66","volume":"33","author":"DL Wells","year":"2016","unstructured":"Wells DL, Popish S, Kay C, Torrise V, Christopher ML. VA Academic detailing service: implementation and lessons learned. Fed Pract. 2016;33:66\u20139.","journal-title":"Fed Pract"},{"key":"991_CR53","unstructured":"Pharmacists. Bureau of labor statistics. Available from: https:\/\/www.bls.gov\/oes\/2023\/may\/oes291051.htm"},{"key":"991_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108568","volume":"221","author":"JR Langabeer","year":"2021","unstructured":"Langabeer JR, Stotts AL, Bobrow BJ, Wang HE, Chambers KA, Yatsco AJ, et al. Prevalence and charges of opioid-related visits to U.S. emergency departments. Drug Alcohol Depend. 2021;221: 108568.","journal-title":"Drug Alcohol Depend"},{"key":"991_CR55","unstructured":"Ambulance Fee Schedule Public Use Files | CMS. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/ambulance\/ambulance-fee-schedule-public-use-files"},{"key":"991_CR56","unstructured":"Consumer Price Index (CPI) Databases. Bureau of Labor Statistics. Available from: https:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"991_CR57","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s11136-024-03729-6","volume":"33","author":"T Patton","year":"2024","unstructured":"Patton T, Boehnke JR, Goyal R, Manca A, Marienfeld C, Martin NK, et al. Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making. Qual Life Res. 2024;33:2783\u201396.","journal-title":"Qual Life Res"},{"key":"991_CR58","unstructured":"Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report. ASPE. 2019. Available from: http:\/\/aspe.hhs.gov\/reports\/non-fatal-opioid-overdose-associated-health-outcomes-final-summary-report-0"},{"key":"991_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.07.031","volume":"75","author":"T Townsend","year":"2020","unstructured":"Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, Hutton DW. Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States. Int J Drug Policy. 2020;75: 102536.","journal-title":"Int J Drug Policy"},{"key":"991_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0272989X09349961","volume":"30","author":"O Rivero-Arias","year":"2010","unstructured":"Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30:341\u201354.","journal-title":"Med Decis Making"},{"key":"991_CR61","first-page":"247","volume":"18","author":"LY Wong","year":"2016","unstructured":"Wong LY, Bellomo R, Robbins R, Martensson J, Kanaan R, Newton R, et al. Long-term outcomes after severe drug overdose. Crit Care Resusc. 2016;18:247\u201354.","journal-title":"Crit Care Resusc"},{"key":"991_CR62","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2015","unstructured":"Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"991_CR63","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68\u201380.","journal-title":"Med Decis Making"},{"key":"991_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","volume":"12","author":"CP Lee","year":"2009","unstructured":"Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12:80\u20137.","journal-title":"Value Health."},{"key":"991_CR65","unstructured":"Neumann E by PJ, Sanders GD, Russell LB, Siegel JE, Ganiats and TG, editors. Cost-Effectiveness in Health and Medicine. Second Edition, New to this Edition:, Second Edition, New to this Edition: Oxford, New York: Oxford University Press; 2016."},{"key":"991_CR66","unstructured":"National Academies of Sciences E, Division H and M, Policy B on HS, Abuse C on PM and RS to APO, Phillips JK, Ford MA, et al. Trends in opioid use, harms, and treatment. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. National Academies Press (US); 2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK458661\/"},{"key":"991_CR67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479\u2013500.","journal-title":"Pharmacoeconomics"},{"key":"991_CR68","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40258-021-00700-1","volume":"20","author":"H Thom","year":"2022","unstructured":"Thom H. Deterministic and probabilistic analysis of a simple Markov model: how different could they be? Appl Health Econ Health Policy. 2022;20:447\u20139.","journal-title":"Appl Health Econ Health Policy"},{"key":"991_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1192\/bjp.187.2.106","volume":"187","author":"E Fenwick","year":"2005","unstructured":"Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106\u20138.","journal-title":"Br J Psychiatry"},{"key":"991_CR70","doi-asserted-by":"crossref","unstructured":"Bounthavong M, Christopher MLD, Veenstra DL, Basu A, Devine EB. Exploring providers\u2019 perception to naloxone education for opioid overdose after receiving academic detailing at the U.S. Department of Veterans Affairs. J Pharm Pract. 2021;8971900211053282.","DOI":"10.1177\/08971900211053282"},{"key":"991_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111087","volume":"255","author":"\u00d8B Ericson","year":"2024","unstructured":"Ericson \u00d8B, Eide D, Lobmaier P, Clausen T. Mortality risk and causes of death among people who use opioids in a take-home naloxone cohort. Drug Alcohol Depend. 2024;255: 111087.","journal-title":"Drug Alcohol Depend"},{"key":"991_CR72","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","volume":"23","author":"AH Briggs","year":"2002","unstructured":"Briggs AH, O\u2019Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377\u2013401.","journal-title":"Annu Rev Public Health"},{"key":"991_CR73","first-page":"414","volume":"8","author":"TJ Van Hoof","year":"2015","unstructured":"Van Hoof TJ, Harrison LG, Miller NE, Pappas MS, Fischer MA. Characteristics of academic detailing: results of a literature review. Am Health Drug Benefits. 2015;8:414\u201322.","journal-title":"Am Health Drug Benefits."},{"key":"991_CR74","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/QAD.0b013e3283522d81","volume":"26","author":"RJ Lubelchek","year":"2012","unstructured":"Lubelchek RJ, Beavis KG, Gonzalez M, Kendrick SR, Roberts RR, Barker DE. Can we broaden the applicability of HIV transmission cluster analyses? AIDS. 2012;26:1043\u20134.","journal-title":"AIDS"},{"key":"991_CR75","first-page":"e16","volume":"60","author":"M Jin","year":"2014","unstructured":"Jin M, Gagnon A, Levine M, Thabane L, Rodriguez C, Dolovich L. Patient-specific academic detailing for smoking cessation: feasibility study. Can Fam Physician. 2014;60:e16-23.","journal-title":"Can Fam Physician"},{"key":"991_CR76","doi-asserted-by":"publisher","first-page":"511","DOI":"10.18433\/J3KK6C","volume":"16","author":"HK Chhina","year":"2013","unstructured":"Chhina HK, Bhole VM, Goldsmith C, Hall W, Kaczorowski J, Lacaille D. Effectiveness of academic detailing to optimize medication prescribing behaviour of family physicians. J Pharm Pharm Sci. 2013;16:511\u201329.","journal-title":"J Pharm Pharm Sci"},{"key":"991_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugpo.2018.02.008","volume":"55","author":"C Keane","year":"2018","unstructured":"Keane C, Egan JE, Hawk M. Effects of naloxone distribution to likely bystanders: results of an agent-based model. Int J Drug Policy. 2018;55:61\u20139.","journal-title":"Int J Drug Policy"},{"key":"991_CR78","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48732","volume":"7","author":"E Tatara","year":"2024","unstructured":"Tatara E, Ozik J, Pollack HA, Schneider JA, Friedman SR, Harawa NT, et al. Agent-based model of combined community- and jail-based take-home naloxone distribution. JAMA Netw Open. 2024;7: e2448732.","journal-title":"JAMA Netw Open"},{"key":"991_CR79","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1257\/pol.20230135","volume":"16","author":"M Jacobson","year":"2024","unstructured":"Jacobson M, Powell D. Price sensitivity and information barriers to the take-up of naloxone. Am Econ J Econ Policy. 2024;16:463\u201390.","journal-title":"Am Econ J Econ Policy."},{"key":"991_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2024.102917","volume":"97","author":"R Smart","year":"2024","unstructured":"Smart R, Powell D, Pacula RL, Peet E, Abouk R, Davis CS. Investigating the complexity of naloxone distribution: which policies matter for pharmacies and potential recipients. J Health Econ. 2024;97: 102917.","journal-title":"J Health Econ"},{"key":"991_CR81","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/1715163520958435","volume":"153","author":"R So","year":"2020","unstructured":"So R, Al Hamarneh Y, Barnes M, Beazely MA, Boivin M, Laroche J, et al. The status of naloxone in community pharmacies across Canada. Can Pharm J (Ott). 2020;153:352\u20136.","journal-title":"Can Pharm J (Ott)."},{"key":"991_CR82","unstructured":"U.S. Food and Drug Administration. FDA approves first over-the-counter naloxone nasal spray. FDA. FDA; 2024. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray"},{"key":"991_CR83","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1920","volume":"5","author":"GT Marley","year":"2024","unstructured":"Marley GT, Annis IE, Egan KL, Delamater P, Carpenter DM. Naloxone availability and cost after transition to an over-the-counter product. JAMA Health Forum. 2024;5: e241920.","journal-title":"JAMA Health Forum."},{"key":"991_CR84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.05.014","volume":"190","author":"AK Gertner","year":"2018","unstructured":"Gertner AK, Domino ME, Davis CS. Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug Alcohol Depend. 2018;190:37\u201341.","journal-title":"Drug Alcohol Depend"},{"key":"991_CR85","doi-asserted-by":"publisher","unstructured":"Abouk R, Pacula RL, Powell D. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. JAMA Intern Med. 2019 Jun 1;179(6):805\u201311. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0272. PMID: 31058922; PMCID: PMC6503576.","DOI":"10.1001\/jamainternmed.2019.0272"},{"key":"991_CR86","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/healthcare9101257","volume":"9","author":"JA Asamani","year":"2021","unstructured":"Asamani JA, Alugsi SA, Ismaila H, Nabyonga-Orem J. Balancing equity and efficiency in the allocation of health resources\u2014Where is the middle ground? Healthcare (Basel). 2021;9:1257.","journal-title":"Healthcare (Basel)."},{"key":"991_CR87","unstructured":"Baciu A, Negussie Y, Geller A, Weinstein JN. The state of health disparities in the United States. Communities in action: pathways to health equity. National Academies Press (US); 2017. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK425844\/"},{"key":"991_CR88","volume-title":"Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs","year":"2020","unstructured":"Cookson R, Griffin S, Culyer AJ, editors. Distributional cost-effectiveness analysis: quantifying health equity impacts and trade-offs. 1st ed. New York: Oxford University Press; 2020.","edition":"1"},{"key":"991_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","volume":"36","author":"M Asaria","year":"2016","unstructured":"Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36:8\u201319.","journal-title":"Med Decis Making"},{"key":"991_CR90","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","volume":"20","author":"R Cookson","year":"2017","unstructured":"Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health. 2017;20:206\u201312.","journal-title":"Value Health."},{"key":"991_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2022.104712","volume":"161","author":"M Bounthavong","year":"2022","unstructured":"Bounthavong M, Shayegani R, Manning JM, Marin J, Spoutz P, Hoffman JD, et al. Comparison of virtual to in-person academic detailing on naloxone prescribing rates at three U.S. Veterans Health Administration regional networks. Int J Med Inform. 2022;161: 104712.","journal-title":"Int J Med Inform"},{"key":"991_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2023-002444","volume":"13","author":"BH Garcia","year":"2024","unstructured":"Garcia BH, Langaas HC, Jahnsen JA, Schj\u00f8tt J, Nilsen T, Lehnbom EC. Exploring virtual delivery of academic detailing to general practitioners compared with in-person delivery: a qualitative study. BMJ Open Qual. 2024;13: e002444.","journal-title":"BMJ Open Qual."},{"key":"991_CR93","doi-asserted-by":"crossref","unstructured":"Spencer MR, Garnett MF, Mini\u00f1o AM. Drug overdose deaths in the United States, 2002\u20132022. NCHS Data Brief, no 491. Hyattsville, MD: National Center for Health Statistics; 2024 Mar. Report No.: 491. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db491.htm","DOI":"10.15620\/cdc:135849"},{"key":"991_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309938","volume":"19","author":"D Kline","year":"2024","unstructured":"Kline D, Hepler SA, Krawczyk N, Rivera-Aguirre A, Waller LA, Cerd\u00e1 M. A state-level history of opioid overdose deaths in the United States: 1999\u20132021. PLoS\u00a0One. 2024;19: e0309938.","journal-title":"PLoS\u00a0One"},{"key":"991_CR95","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2105\/AJPH.2024.307745","volume":"114","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, Wang J, Holland KM, Ehlman DC, Welder LE, Miller KD, et al. Trends in drug overdose deaths by intent and drug categories, United States, 1999\u20132022. Am J Public Health. 2024;114:1081\u20135.","journal-title":"Am J Public Health"},{"key":"991_CR96","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.36076\/ppj.2017.s151","volume":"20","author":"M Trotter Davis","year":"2017","unstructured":"Trotter Davis M, Bateman B, Avorn J. Educational outreach to opioid prescribers: the case for academic detailing. Pain Physician. 2017;20:S147\u201351.","journal-title":"Pain Physician"},{"key":"991_CR97","doi-asserted-by":"crossref","unstructured":"Kulbokas V, Hanson KA, Smart MH, Mandava MR, Lee TA, Pickard AS. Academic detailing interventions for opioid-related outcomes: a scoping review. Drugs Context. 2021;10:2021-7\u20137.","DOI":"10.7573\/dic.2021-7-7"},{"key":"991_CR98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12954-019-0352-0","volume":"17","author":"BL Hanson","year":"2020","unstructured":"Hanson BL, Porter RR, Z\u00f6ld AL, Terhorst-Miller H. Preventing opioid overdose with peer-administered naloxone: findings from a rural state. Harm Reduct J. 2020;17:4.","journal-title":"Harm Reduct J"},{"key":"991_CR99","first-page":"28","volume":"9","author":"J Watkins","year":"2023","unstructured":"Watkins J. Understanding value: US Payers\u2019 perspectives. Value Outcomes Spotlight. 2023;9:28\u201331.","journal-title":"Value Outcomes Spotlight."},{"key":"991_CR100","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s11606-015-3394-3","volume":"30","author":"IA Binswanger","year":"2015","unstructured":"Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med. 2015;30:1837\u201344.","journal-title":"J Gen Intern Med"},{"key":"991_CR101","doi-asserted-by":"publisher","first-page":"004695802412761","DOI":"10.1177\/00469580241276144","volume":"61","author":"SA Dee","year":"2024","unstructured":"Dee SA, Delonnay K-A, Bernard D, Jean-Baptiste F. Identifying provider barriers to the implementation of opioid harm reduction methods: an initial narrative review. Inquiry. 2024;61:00469580241276144.","journal-title":"Inquiry"},{"key":"991_CR102","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1080\/08897077.2022.2060423","volume":"43","author":"E Gugala","year":"2022","unstructured":"Gugala E, Briggs O, Moczygemba LR, Brown CM, Hill LG. Opioid harm reduction: a scoping review of physician and system-level gaps in knowledge, education, and practice. Substance Abuse. 2022;43:972\u201387.","journal-title":"Substance Abuse"},{"key":"991_CR103","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11524-006-9120-z","volume":"84","author":"L Beletsky","year":"2007","unstructured":"Beletsky L, Ruthazer R, Macalino GE, Rich JD, Tan L, Burris S. Physicians\u2019 knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health. 2007;84:126\u201336.","journal-title":"J Urban Health"},{"key":"991_CR104","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.18549\/PharmPract.2019.3.1591","volume":"17","author":"D Hargraves","year":"2019","unstructured":"Hargraves D, White CC, Mauger MR, Puthota A, Pallerla H, Wigle P, et al. Evaluation of an interprofessional naloxone didactic and skills session with medical residents and physician assistant learners. Pharm Pract (Granada). 2019;17:1591.","journal-title":"Pharm Pract (Granada)."},{"key":"991_CR105","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/j.amepre.2021.05.042","volume":"61","author":"GP Guy","year":"2021","unstructured":"Guy GP, Khushalani JS, Jackson H, St. Clair Sims R, Arifkhanova A. Trends in state-level pharmacy-based naloxone dispensing rates, 2012\u20132019. Am J Prev Med. 2021;61:e289\u201395.","journal-title":"Am J Prev Med"},{"key":"991_CR106","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11606-018-4397-7","volume":"33","author":"JE Freise","year":"2018","unstructured":"Freise JE, McCarthy EE, Guy M, Steiger S, Sheu L. Increasing naloxone co-prescription for patients on chronic opioids: a student-led initiative. J Gen Intern Med. 2018;33:797\u20138.","journal-title":"J Gen Intern Med"},{"key":"991_CR107","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2019.9b2","author":"T D\u2019Arrigo","year":"2019","unstructured":"D\u2019Arrigo T. Naloxone dispensing is increasing, but remains low overall. PN. 2019. https:\/\/doi.org\/10.1176\/appi.pn.2019.9b2.","journal-title":"PN"},{"key":"991_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100244","volume":"11","author":"SG Weiner","year":"2024","unstructured":"Weiner SG, Miller EN, Burke B, Clear B. Naloxone prescription fills and use by patients treated for opioid use disorder by telehealth. Drug Alcohol Depend Reports. 2024;11: 100244.","journal-title":"Drug Alcohol Depend Reports."},{"key":"991_CR109","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/epirev\/mxaa011","volume":"42","author":"CM Jones","year":"2020","unstructured":"Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42:154\u201366.","journal-title":"Epidemiol Rev"},{"key":"991_CR110","doi-asserted-by":"publisher","unstructured":"Spencer MR, Cisewski JA, Warner M, Garnett MF. Drug overdose deaths involving xylazine: United States, 2018\u20132021. Hyattsville, MD: National Center for Health Statistics; 2023 Jun. Report No.: 30. Available from: https:\/\/doi.org\/10.15620\/cdc:129519.","DOI":"10.15620\/cdc:129519"},{"key":"991_CR111","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50630","volume":"7","author":"M Cano","year":"2024","unstructured":"Cano M, Daniulaityte R, Marsiglia F. Xylazine in overdose deaths and forensic drug reports in US states, 2019\u20132022. JAMA Netw Open. 2024;7: e2350630.","journal-title":"JAMA Netw Open"},{"key":"991_CR112","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1001\/jama.2023.8625","volume":"329","author":"R Rubin","year":"2023","unstructured":"Rubin R. Here\u2019s what to know about Xylazine, aka Tranq, the animal tranquilizer increasingly found in illicit fentanyl samples. JAMA. 2023;329:1904\u20136.","journal-title":"JAMA"},{"key":"991_CR113","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/jcpt.13462","volume":"46","author":"JV Pergolizzi","year":"2021","unstructured":"Pergolizzi JV, Dahan A, Ann LeQuang J, Raffa RB. Overdoses due to fentanyl and its analogues (F\/FAs) push naloxone to the limit. J Clin Pharm Ther. 2021;46:1501\u20134.","journal-title":"J Clin Pharm Ther"},{"key":"991_CR114","volume":"15","author":"J Pergolizzi","year":"2023","unstructured":"Pergolizzi J, LeQuang JAK, Magnusson P, Miller TL, Breve F, Varrassi G. The new stealth drug on the street: a narrative review of Xylazine as a street drug. Cureus. 2023;15: e40983.","journal-title":"Cureus."},{"key":"991_CR115","doi-asserted-by":"publisher","first-page":"1280289","DOI":"10.3389\/fphar.2023.1280289","volume":"14","author":"MA Smith","year":"2023","unstructured":"Smith MA, Biancorosso SL, Camp JD, Hailu SH, Johansen AN, Morris MH, et al. \u201cTranq-dope\u201d overdose and mortality: lethality induced by fentanyl and xylazine. Front Pharmacol. 2023;14:1280289.","journal-title":"Front Pharmacol"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00991-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:08:51Z","timestamp":1760962131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00991-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00991-8","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"8 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OY received Gateway to Research Awards from the American Foundation for Pharmaceutical Education (AFPE) between 2022\u20132023 and research funding from University of California, San Diego from the 2022 Summer Research Program.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MB has received consulting fees from Merck & Company and research funding from the National Institutes of Health and the University of California San Diego. OY is currently in a fellowship sponsored by AbbVie, Inc and the University of Washington.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The model and data supporting the findings of this study are provided in the supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The model and data supporting the findings of this study are provided in the supplementary materials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"OY and MB conceptualized and design of the study, acquired the data, and interpreted the findings. OY developed the model, performed validation, and was the primary author of the manuscript. MB supervised the project, reviewed the model and edited the manuscript. The authors whose names appear on the submission have contributed sufficiently to the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}